80 results about "Blood cancers" patented technology

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

The invention provides a double-site irreversible Brutons tyrosine kinase inhibitor, a drug combination containing the same and application thereof to the anti-tumor field. The compound provided by the invention has an anti-proliferation inhibiting effect to tumor cell stains such as A549, SGC7901, MCF-7, PC-9 and HL-60, and can be applied to drugs for treating solid tumors or blood cancers related to human or animal cell proliferation; the compound provided by the invention has a better pharmacokinetic property and can be applied to treating solid tumors or blood cancers related to human or animal cell proliferation or autoimmune diseases through oral taking; the compound provided by the invention has a double-site response characteristic.

The present invention relates to a medicine for curing cancers, including 13 Chinese medicinal materials of glaucescent fissistigma root, bushy sophora, root, semiaquilegia tuber, zedoary, prunella spike, pig's bile and others. It is good in therapeutic effect, has no toxic side effect, can eliminate toxic side effect produced in radiotherapy and chemotherapy, and can raise immunity of body, except for blood cancer it can be used for curing all the cancers.

The invention provides an application of osthole in preparing anti-angiogenic drugs. The osthole can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi's sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget's disease angiogenesis. The invention also provides the application of a compound containing effective dose of osthole and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The invention relates to a Chinese herbal medicine composition for treating liver cancer, stomach cancer, lung cancer and leukemia, which is prepared from the following medicines in parts by weight: 4-8 parts of bluegrass overlord, 3-9 parts of dried orange peel, 4-7 parts of gardenia, 6-9 parts of bark of white mulberry, 2-5 parts of radix rehmanniae, 3-7 parts of isatis leaf, 3-8 parts of white peony root, 2-6 parts of white ginseng, 3-9 parts of radix notoginseng, 3-7 parts of madder, 4-6 parts of atractylodes rhizome, 3-7 parts of cassia seed, 4-7 parts of hyacinth bletilla, 2-3 parts of Chinese yam, 3-5 parts of euryale seed, 2-4 parts of purple common perilla, 7-10 parts of honey, 5-9 parts of milk vetch, 4-9 parts of dangshen, 5-9 parts of gentian, 4-8 parts of ganoderma, 2-4 parts of shiandra, 3-5 parts of gingko, 5-10 parts of gastrodia tuber, 4-7 parts of balloonflower, 3-5 parts of almond, 5-7 parts of rhizoma anemarrhenae, 4-8 parts of sealwort, 9-10 parts of loquat leaf, 4-12 parts of red sage root, 5-9 parts of angelica, 4-8 parts of eucommia, 5-7 parts of chuanxiong rhizome, 3-7 parts of chrysanthemum and 6-9 parts of tuckahoe. The preparation method of the Chinese herbal medicine composition comprises the following steps of: cleaning and baking the medicines, evenly mixing the medicines, crushing the mixture, and preparing the Chinese herbal medicine composition. By using the composition provided by the invention for treating liver cancer, stomach cancer, lung cancer and leukemia, all indexes of a patient can be obviously improved, the immunologic function of the patient can be enhanced, and the physique can be recovered, thereby achieving an ideal effect of healing.

The present invention relates to the use of a compound of formula 3 or a salt thereof to prepare a medicament or phototherapeutic agent for treating the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; SARS virus infection; coronavirus Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers, including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophageal cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary tract cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancer. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of the compound of formula 3 or a salt thereof to prepare a photodiagnostic agent for detecting the above-mentioned diseases and the following diseases, including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infections, viral infections, chlamydial infections, bacterial infections, or parasitic diseases, HIV viral infections, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease, and skin diseases. The present invention also relates to methods for detecting the above diseases using photodiagnostic agents. The present invention further relates to a method for low-temperature sterilization of surgical devices or other devices, including the steps of: providing a compound of Chemical Formula 3 or a salt thereof on the device; and subjecting the device to radiation treatment or sonication treatment. The invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The invention also relates to the use of such MRI enhancers for performing MRI scans.

A method of diagnosing, quantifying, treating, monitoring or evaluating a condition in a subject is provided. The method comprises obtaining a sample from the subject, detecting and determining the presence or quantity of one or more than one human papilloma virus (HPV) in the sample, wherein the presence or quantity of the one or more than one HPV is indicative of the presence of the condition in the subject or an increased likelihood of the subject for developing the condition when compared to a control. The condition may comprise autoimmune disorders, chronic neurodegenerative diseases, neurodevelopmental disorder, neoplasm, blood cancers such as lymphoma or leukemia, Chronic Fatigue Syndrome or Fibromyalgia.

The components of a brew / extract of leaves or other parts of the papaya plant (Carica papaya) or fractionated components thereof are effective in the prevention or treatment of stomach cancer, lung cancer, pancreatic cancer, colon cancer or other solid cancers, or lymphoma, leukemia or other blood cancers, and are very safe with few side effects, making their medical significance extremely high. In addition, food compositions comprising a papaya plant (Carica papaya) extract component as an effective ingredient for the prevention or amelioration of cancer are highly expected to become functional foods contributing to the preservation and promotion of human health.

The invention provides a novel method capable of largely and fast enriching and culturing stem / progenitor cell subsets in blood suspended cancer cells by an embryonic stem cell culture medium, and a culture medium composition. The embryonic stem cell culture medium is adopted, stem / progenitor cell cloning of blood cancer cells can be selected in a semisolid culture medium through adding other factors and inhibitor micromolecule compounds inhibiting glycogen synthase kinase (GSK) signal channels and tyrosine kinase, and the cloning can be massively cultured in a suspended way and amplified in the blood cancer stem cell culture medium provided by the invention. The blood cancer stem cells obtained by the method have special marks in aspects of cell morphology, stem cell gene expression, stem cell surface characteristic antigen expression and the like, the stem cell characteristic of sieved suspended stem cells is closer to that of embryonic stem cells, and the obvious drug resistance on chemotherapeutic drug is realized. The novel method and the culture medium composition have good application prospects in the aspects of blood suspended cancer stem cell enrichment and cloning, cancer stem cell special drum screening and identification and the like.

The invention relates to tetrahydroindazolone or tetrahydroindazolone-substituted indazole derivatives with right general formula (I) or (II) and pharmaceutically acceptable salt thereof. The compounds and the pharmaceutically acceptable salt thereof are characterized by inhibiting growth of tumor cells and malignant cells. The tumor cells comprise cancer cells such as breast cancer, lung cancer, cervical carcinoma, rectum cancer, prostatic cancer, liver cancer, blood cancer and the like, thus the tetrahydroindazolone or tetrahydroindazolone-substituted indazole derivatives and the salt thereof can be used for preparing drugs for preventing and treating the breast cancer, the lung cancer, the cervical carcinoma, the rectum cancer, the prostatic cancer, the liver cancer and the blood cancer.

The invention provides a new medicament for treating leukemia, which is prepared from 39 raw material drugs, such as taxus chinensis (tree bark), tender catchweed bedstraw herb, prismatomeria tetrandra, isatis indigotica fort, tuber fleeceflower stem, Yunnan fringed iris herb, fructus corni, hemlock parsley, turtle shell and the like, wherein the taxus chinensis (tree bark) contains 'taxol' which is the top anti-cancer medicament in the world, can be combined with trace of albumin, so that the albumin is accelerated to be aggregated, mitosis of cancer cells can be inhibited, and proliferation of the cancer cells can be effectively stopped. The medicament also comprises the tender catchweed bedstraw herb, suncured ginseng, prismatomeria tetrandra, isatis indigotica fort, tuber fleeceflower stem, Yunnan fringed iris herb, fructus corni, hemlock parsley and turtle shell, so that growth and development of the cancer cells can be controlled, the cancer resistance of a human body can be reinforced, the circulation and metabolic function of the human body can be improved, virus accumulated in the human body is removed outside the body through urine and defecation to achieve the function of preventing cancer. The medicament adopts the Chinese medicaments capable of nourishing yin and supplementing kidney, supplying vital energy, nourishing and activating blood, tonifying qi and controlling blood, softening hardness to dissipate stagnation, removing toxicity and tonifying middle-Jiao and coordinating drug actions of a prescription, administration is increased or reduced according to the course development and classification of the leukemia to achieve the best treatment effect. 38 leukemia cases are treated non-selectively in clinical application, and the total effective rate is over 90 percent.

The present invention provides methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).

The invention provides a small molecular activator taking human M2 type pyruvate kinase (M2 type pyruvate kinase, PKM2) as a target spot and application of the small molecular activator, and belongs to the technical field of pharmacy. According to the small molecular activator, the PKM2 is taken as the target spot, and the small molecule activator is screened by combining virtual screening based on butt joint and in-vitro biological activity evaluation. In-vitro activity test results show that two screened compounds have good PKM2 activation activity and good cancer cell inhibition activity, and discovered small molecules can provide a basis for research and development of new drugs for treating PKM2 related diseases, such as cervical cancer, breast cancer, ovarian cancer, prostate cancer,liver cancer, lung cancer, pancreatic cancer, colorectal cancer, leukemia, melanoma and multiple myeloma. A lead compound of the small molecular activator can be further optimized in structure, and arelatively good application prospect is achieved.

The invention relates to anti-leukemia effects of a neurokinin receptor antagonist SR140333, and relates specifically to methods of treating leukemia and relieving leukemia symptoms for subjects, to a method of inhibiting a proliferation of leukemia cells, to uses of the neurokinin receptor antagonist in drugs, medicaments or pharmaceutical compositions utilized for treating leukemia and relieving leukemia symptoms, or inhibiting a proliferation of leukemia cells, and to a pharmaceutical product comprising a neurokinin receptor antagonist as an active ingredient and a specification of the pharmaceutical product.

The invention belongs to the technical field of medicine, and particularly relates to optical isomers represented by the formula (II) and the formula (III) and used as tyrosine kinase inhibitors, and pharmaceutically acceptable salts thereof. The invention also relates to preparation methods of the optical isomers, pharmaceutical preparations containing the optical isomers, and the optical isomers playing important roles in preparation of drugs for prevention and / or treatment of B cell related leukemia (such as B cell chronic lymphocytic cancer, non-hodgkin lymphoma and the like), inflammatory and autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus and the like).

The invention provides a tetracyclic anthraquinone with selective absorption and selective displacement, which is suitable for diseases that can be effectively treated by all tetracyclic anthraquinones, comprising but not limited to intestinal cancer, liver cancer, gastric cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, glioma, lymph cancer, skin cancer, melanoma, thyroid cancer, multiple myeloma and leukaemia.

The present invention provides a biological product capable of resisting stenotrophomonas maltophilia and Pseudomonas aeruginosa infection and raising the body fluid immunity and cell immunity of malignant tumor patient. The biological product is prepared with stenotrophomonas maltophilia, and may be prepared into various kinds of immunological preparations and immune regulating preparations. The medicine of the present invention has the special effect of preventing and treating stenotrophomonas maltophilia and Pseudomonas aeruginosa infection and treating ascites carcinoma and leukemia.

Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes (''phosphaplatin compounds''), especially (R,R)-l,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or ''PT-112''), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.

The present invention relates to aripiptan and cytarabine composition and an anti-leukemia effect thereof, in particular to a method for treating leukemia in a subject, relieving leukemia symptoms inthe subject or inhibiting proliferation of leukemia cells. The method comprises the step of administering aripiptan combined with cytarabine to subjects. Further, the invention relates to a leukemia treatment drug. The drug comprises aripiptan and cytarabine, and an optional pharmaceutically acceptable carrier.

The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and some blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The present invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders) related to hedgehog signaling.

The invention discloses all-trans retinoic acid-aryl metal complexes which are obtained by combining small molecules with anti-leukemia activity with aryl ruthenium and iridium metal precursors through a click reaction, and the complexes have the characteristics of corresponding active molecules and also have the anti-leukemia activity. The aromatic metal has the characteristics of good solubility, small toxicity, low drug resistance, high cell intake, easy metabolism and the like, and can realize targeted treatment on leukemia cells; the complex is simple in preparation process, easy to operate and high in yield, and has very high commercial value and application prospect in the aspect of preparing anti-leukemia drugs.

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

The present invention relates to the combination of at least one agent and a reduced calorie intake for use in the treatment of a blood cancer. In particular the agent is a CD20 inhibitor Bruton's tyrosine kinase inhibitor, a phosphoinositide 3-kinase inhibitor, a class I and / class II histone deacetylase inhibitor, a non-taxane replication inhibitor or a proteasome inhibitor. The combination is advantageous in that it sensitize cancer cells to said agent while it protects normal cells from toxicity induced by said agent.

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and / or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and / or inhibit the transcription of disease-related genes in the patient (or in a biological sample).